Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

AZN.US Logo

AZN.US - Current Price

$93.63

Company Information

▼
Company Name
AstraZeneca PLC ADR
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
ISIN: US0463531089
CIK: 0000901832
CUSIP: 046353108
Currency: USD
Full Time Employees: 94,300
Phone: 44 20 3749 5000
Website: https://www.astrazeneca.com
Fiscal Year End: December
IPO Date: May 12, 1993
Description:

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Address:

1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

Directors & Officers

▼
Name Title Year Born
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. CEO & Executive Director 1959
Dr. Aradhana Sarin M.D. CFO & Executive Director 1974
Ms. Pam P. Cheng EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board 1970
Mr. Andrew P. Barnett Head of Investor Relations NA
Mr. Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board NA
Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit NA
Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology R&D 1966
Ms. Iskra Reic Executive Vice President of International NA
Mr. David Fredrickson Executive Vice-President of Oncology Haematology Business Unit 1975
Ms. Ruth March Senior VP of Precision Medicine - R&D Oncology NA

Shares Statistics

▼
Shares Outstanding: 3.10B
Shares Float: 1.54B
% Insiders: 0.20%
% Institutions: 1,677.80%
Short % Float: 0.35%

Valuation Metrics

▼
Enterprise Value: $317.62B
Trailing P/E: 31.11
Forward P/E: 18.18

Financial Highlights

▼
Market Cap: $290.31B
EBITDA: $20.42B
P/E Ratio: $31.11
PEG Ratio: $1.08
Book Value: $29.59
Dividend/Share: $3.13
Dividend Yield: 1.67%
Earnings/Share: $3.01
Profit Margin: 16.17%
Operating Margin: 24.11%
ROA (TTM): 9.06%
ROE (TTM): 21.67%
Revenue (TTM): $58.13B
Revenue/Share (TTM): $3.11
Earnings Growth (YOY): 78.00%
Revenue Growth (YOY): 12.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 1.09 N/A -10,000.00%
Sep 30, 2025 1.19 1.14 N/A 438.60%
Jun 30, 2025 0.79 0.88 N/A -1,022.73%
Mar 31, 2025 1.25 1.12 N/A 1,160.71%
Dec 31, 2024 1.05 1.04 N/A 96.15%
Sep 30, 2024 1.04 1.03 N/A 97.09%
Jun 30, 2024 0.99 1.20 N/A -1,750.00%
Mar 31, 2024 1.03 1.22 N/A -1,557.38%
Dec 31, 2023 0.73 0.79 N/A -759.49%
Sep 30, 2023 0.87 0.85 N/A 235.29%
Jun 30, 2023 1.08 0.95 N/A 1,368.42%
Mar 31, 2023 0.96 1.07 N/A -1,028.04%
Dec 31, 2022 0.69 0.67 N/A 298.51%
Sep 30, 2022 0.84 0.72 N/A 1,666.67%
Jun 30, 2022 0.86 0.77 N/A 1,168.83%
Mar 31, 2022 0.95 0.83 N/A 1,445.78%
Dec 31, 2021 0.84 0.73 N/A 1,506.85%
Sep 30, 2021 0.54 0.62 N/A -1,290.32%
Jun 30, 2021 0.45 0.43 N/A 465.12%
Mar 31, 2021 0.82 0.75 N/A 933.33%
Dec 31, 2020 0.54 0.68 N/A -2,058.82%
Sep 30, 2020 0.47 0.44 N/A 681.82%
Jun 30, 2020 0.48 0.44 N/A 909.09%
Mar 31, 2020 0.53 0.47 N/A 1,276.60%
Dec 31, 2019 0.45 0.59 N/A -2,372.88%
Sep 30, 2019 0.50 0.45 N/A 1,111.11%
Jun 30, 2019 0.37 0.30 N/A 2,333.33%
Mar 31, 2019 0.45 0.42 N/A 714.29%
Dec 31, 2018 0.79 0.76 N/A 394.74%
Sep 30, 2018 0.35 0.40 N/A -1,250.00%
Jun 30, 2018 0.35 0.30 N/A 1,666.67%
Mar 31, 2018 0.24 0.34 N/A -2,941.18%
Dec 31, 2017 0.65 0.47 N/A 3,829.79%
Sep 30, 2017 0.56 0.55 N/A 181.82%
Jun 30, 2017 0.44 0.42 N/A 476.19%
Mar 31, 2017 0.50 0.40 N/A 2,500.00%
Dec 31, 2016 0.61 0.59 N/A 338.98%
Sep 30, 2016 0.66 0.74 N/A -1,081.08%
Jun 30, 2016 0.83 0.76 N/A 921.05%
Mar 31, 2016 0.48 0.48 N/A 0.00%
Dec 31, 2015 0.47 0.44 N/A 681.82%
Sep 30, 2015 0.52 0.77 N/A -3,246.75%
Jun 30, 2015 0.60 0.51 N/A 1,764.71%
Mar 31, 2015 0.54 0.53 N/A 188.68%
Dec 31, 2014 0.38 0.43 N/A -1,162.79%
Sep 30, 2014 0.53 0.52 N/A 192.31%
Jun 30, 2014 0.65 0.55 N/A 1,818.18%
Mar 31, 2014 0.59 0.62 N/A -483.87%
Dec 31, 2013 0.62 0.61 N/A 163.93%
Sep 30, 2013 0.61 0.63 N/A -317.46%
Jun 30, 2013 0.60 0.58 N/A 344.83%
Mar 31, 2013 0.71 0.67 N/A 597.01%
Dec 31, 2012 0.78 0.70 N/A 1,142.86%
Sep 30, 2012 0.76 0.74 N/A 270.27%
Jun 30, 2012 0.77 0.68 N/A 1,323.53%
Mar 31, 2012 0.91 0.89 N/A 224.72%
Dec 31, 2011 0.81 0.78 N/A 384.62%
Sep 30, 2011 0.86 0.84 N/A 238.10%
Jun 30, 2011 0.87 0.91 N/A -439.56%
Mar 31, 2011 1.12 1.08 N/A 370.37%
Dec 31, 2010 0.70 0.67 N/A 447.76%
Sep 30, 2010 0.75 0.75 N/A 0.00%
Jun 30, 2010 0.90 0.80 N/A 1,250.00%
Mar 31, 2010 1.01 0.86 N/A 1,744.19%
Dec 31, 2009 0.71 0.76 N/A -657.89%
Sep 30, 2009 0.84 0.69 N/A 2,173.91%
Jun 30, 2009 0.82 0.70 N/A 1,714.29%
Mar 31, 2009 0.79 0.70 N/A 1,285.71%
Dec 31, 2008 0.63 0.58 N/A 862.07%
Sep 30, 2008 0.66 0.57 N/A 1,578.95%
Jun 30, 2008 0.63 0.54 N/A 1,666.67%
Mar 31, 2008 0.64 0.60 N/A 666.67%
Dec 31, 2007 0.55 0.47 N/A 1,702.13%
Sep 30, 2007 0.52 0.46 N/A 1,304.35%
Jun 30, 2007 0.60 0.52 N/A 1,538.46%
Mar 31, 2007 0.51 0.51 N/A 0.00%
Dec 31, 2006 0.47 0.48 N/A -208.33%
Sep 30, 2006 0.51 0.49 N/A 408.16%
Jun 30, 2006 0.51 0.47 N/A 851.06%
Mar 31, 2006 0.45 0.40 N/A 1,250.00%
Dec 31, 2005 0.39 0.37 N/A 540.54%
Sep 30, 2005 0.38 0.33 N/A 1,515.15%
Jun 30, 2005 0.38 0.28 N/A 3,571.43%
Mar 31, 2005 0.32 0.29 N/A 1,034.48%
Dec 31, 2004 0.30 0.29 N/A 344.83%
Sep 30, 2004 0.28 0.26 N/A 769.23%
Jun 30, 2004 0.25 0.24 N/A 416.67%
Mar 31, 2004 0.24 0.27 N/A -1,111.11%
Dec 31, 2003 0.19 0.20 N/A -500.00%
Sep 30, 2003 0.24 0.17 N/A 4,117.65%
Jun 30, 2003 0.20 0.17 N/A 1,764.71%
Mar 31, 2003 0.27 0.21 N/A 2,857.14%
Dec 31, 2002 0.23 0.21 N/A 952.38%
Sep 30, 2002 0.20 0.18 N/A 1,111.11%
Jun 30, 2002 0.23 0.24 N/A -416.67%
Mar 31, 2002 0.28 0.24 N/A 1,666.67%
Dec 31, 2001 0.89 0.23 N/A 28,695.65%
Sep 30, 2001 0.24 0.21 N/A 1,428.57%
Jun 30, 2001 0.21 0.21 N/A 0.00%
Mar 31, 2001 0.22 N/A N/A N/A
Dec 31, 2000 0.21 0.21 N/A 0.00%
Sep 30, 2000 0.19 0.23 N/A -1,739.13%
Sep 30, 1999 0.19 0.17 N/A 1,176.47%
Jun 30, 1999 0.41 0.24 N/A 7,083.33%
Dec 31, 1998 0.25 0.24 N/A 416.67%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $5.49B $N/A $104.04B $63.16B $40.79B
2023-12-31 $5.84B $N/A $101.12B $61.95B $39.14B
2022-12-31 $6.17B $N/A $96.48B $59.43B $37.04B
2021-12-31 $6.33B $N/A $105.36B $66.08B $39.27B
2020-12-31 $7.83B $N/A $66.73B $51.09B $15.62B
2019-12-31 $5.37B $N/A $61.38B $46.78B $13.13B
2018-12-31 $4.83B $N/A $60.65B $46.61B $12.47B
2017-12-31 $3.32B $N/A $63.35B $46.71B $14.96B
2016-12-31 $5.02B $N/A $62.53B $45.86B $14.85B
2015-12-31 $6.24B $N/A $60.12B $41.62B $18.49B
2014-12-31 $6.36B $N/A $58.60B $38.95B $19.63B
2013-12-31 $9.22B $N/A $55.90B $32.65B $23.22B
2012-12-31 $7.70B $N/A $53.53B $29.58B $23.74B
2011-12-31 $7.57B $N/A $52.83B $29.36B $23.25B
2010-12-31 $11.07B $N/A $56.13B $32.72B $23.21B
2009-12-31 $9.92B $N/A $54.92B $34.10B $20.66B
2008-12-31 $4.29B $N/A $46.95B $30.89B $15.91B
2007-12-31 $5.87B $N/A $47.96B $33.04B $14.78B
2006-12-31 $7.10B $N/A $29.93B $14.52B $15.30B
2005-12-31 $4.98B $N/A $24.84B $11.15B $13.60B
2004-12-31 $4.07B $N/A $25.65B $11.16B $14.40B
2003-12-31 $733.00M $N/A $23.57B $10.32B $13.18B
2002-12-31 $726.00M $N/A $21.58B $10.35B $11.17B
2001-12-31 $1.01B $N/A $26.45B $12.68B $13.71B
2000-12-31 $1.02B $N/A $18.45B $8.90B $9.53B
1999-12-31 $428.79M $N/A $19.81B $9.47B $10.30B
1998-12-31 $341.94M $N/A $8.98B $4.75B $4.17B
1997-12-31 $500.89M $N/A $8.28B $4.66B $3.57B
1996-12-31 $443.54M $N/A $8.56B $4.90B $3.48B
1995-12-31 $251.87M $N/A $7.87B $4.83B $2.88B
1994-12-31 $856.75M $N/A $7.32B $4.59B $2.63B
1993-12-31 $1.35B $N/A $7.42B $5.10B $2.22B
1992-12-31 $465.62M $N/A $6.19B $6.02B $83.42M
1991-12-31 $473.41M $N/A $6.36B $5.45B $782.16M
1990-12-31 $129.24M $N/A $6.10B $5.42B $570.97M

Watchlist

0

No stocks in watchlist